Epigenetics deals with the study of gene expression without altering the gene sequence. The epigenetic change associated with gene expression happens with the modification of the transcription mechanism. The key components that are involved in the regulation of epigenetic transcription are DNA methylation, micro RNA, histone modifications, and non-coding RNA’s.
The global epigenetics drugs and diagnostic technologies market
is primarily driven by increasing geriatric population, rising prevalence of oncology, and non-cancerous disorders. Additionally, advancement in screening techniques and large investments in R&D activities is further driving the growth of the market. Epigenetics drugs have the capability to reverse the aberrant expression of genes that leads to diseases and ailments of various forms.
Healthcare Industry Aids Research to Drive the Epigenetics Drugs Market Globally
In the incidence of development of cancer, cells undergo epigenetics changes that are reversible. As such, healthcare industry is promoting research for cancer epigenetics. Several drugs have been developed for DNA methylation and histone deacetylation that is fueling growth for the epigenetics drugs market. Additionally, drugs targeting epigenetic changes that work independently or in combination with other conventional drugs for cancer are also developed to propel the market. Moreover, increased attention for novel epigenetic indicators for cancers are further driving the epigenetics drugs market.
Globally, the epigenetics drugs and diagnostic technologies market valued US$1.6 billion in 2011. It is expected to grow at CAGR of 19.4% and reach US$5.7 billion by 2018.
DNMT Inhibitors Act as Anti-cancer Agents to Give Thrust to the Epigenetics Drugs Market Globally
The epigenetics drugs and diagnostic technologies market is classified on the basis of mechanism of action, epigenetics diagnostic technologies type, and geographical regions. In terms of mechanism of action, Histone Deacetylase (HDAC) and DNA Methyltransferase (DNMT) account for regulating the gene expression. Of the two, DNMT is further sub-segmented as Decitabine (Dacogen) and Azacitidine (Vidaza). The HDAC inhibitors of the epigenetics drugs and diagnostic technologies market is sub-segmented as Vorinostat (Zolinza) and Romidepsin (Istodax). DNMT inhibitors hold a larger share as it offers better access to target cancerous cells. DNMT is identified as anti-cancer agent for limiting DNA methylation activity.
On the basis of epigenetics diagnostic technologies, the market is segmented into DNA Methylation and Chromatin Immunoprecipitation (Chip). Of the two sub-segments of the epigenetics diagnostic technologies type, DNA methylation accounts for the larger market share owing to its reliability and efficacy tested for a long period.
Increased Prevalence of Cancers in Asia Pacific Drives the Epigenetics Drugs Market
Geography-wise, the epigenetics drugs and diagnostic technologies market is segregated into Europe, Rest of the World (RoW), North America, and Asia Pacific. North America accounts for over half of the global epigenetics market as the region is at the forefront of new technologies and therapies. Thus, the region enjoys maximum revenue share of the epigenetics drugs and diagnostic technologies market globally.
Asia Pacific will have high growth opportunities for the market in coming years due to increased prevalence of different types of cancers in the region. Nearly half a dozen of new cancer types are discovered in Asia in the recent few years.
Product wise, the epigenetics drugs market is highly consolidated as it features only four drugs namely Eisai Pharmaceuticals’ Dacogen, Celgene’s Vidaza, Merck’s Zolinza, and Istodax. Of these, Celgene’s Vidaza drugs held 60% of the market share in 2011. The major players in the epigenetics drugs and diagnostic technologies market are Oncolys BioPharma Inc., Eisai Pharmaceuticals, Celleron Therapeutics Ltd., Epizyme, Inc. Illumina Inc., Chroma Therapeutics Ltd., Spectrum Pharmaceuticals, EnVivo Pharmaceuticals Inc., Topotarget A/S, Astex Pharmaceuticals Inc., Valirx Plc, Merck, MDxHealth, Novartis International AG, Celenge, CellCentric Ltd., Syndax Pharmaceuticals, Inc., Epigentek Group Inc., Merck & Company Inc., Promega Corporation, 4SC AG, Acetylon Pharmaceuticals, Inc., and others.